| Primary |
| Acute Myeloid Leukaemia |
59.5% |
| Pneumonia |
21.6% |
| Myelodysplastic Syndrome |
5.4% |
| Myeloid Leukaemia |
5.4% |
| Prophylaxis |
5.4% |
| Pyrexia |
2.7% |
|
| Acute Febrile Neutrophilic Dermatosis |
14.3% |
| Cardiac Arrest |
7.1% |
| Death |
7.1% |
| Drug Prescribing Error |
7.1% |
| Febrile Neutropenia |
7.1% |
| Gamma-glutamyltransferase Increased |
7.1% |
| Neutropenia |
7.1% |
| Pancytopenia |
7.1% |
| Pneumonia Fungal |
7.1% |
| Pulmonary Toxicity |
7.1% |
| Streptococcal Bacteraemia |
7.1% |
| Tenderness |
7.1% |
| White Blood Cell Disorder |
7.1% |
|
| Secondary |
| Acute Myeloid Leukaemia |
42.6% |
| Product Used For Unknown Indication |
17.4% |
| Prophylaxis |
7.6% |
| Acute Promyelocytic Leukaemia |
5.0% |
| Acute Monocytic Leukaemia |
3.6% |
| Acute Leukaemia |
3.3% |
| Myelodysplastic Syndrome |
2.8% |
| Acute Myeloid Leukemia |
2.2% |
| Infection Prophylaxis |
2.2% |
| Pyrexia |
2.2% |
| Acute Myeloid Leukaemia Recurrent |
1.6% |
| Hypertension |
1.5% |
| Plasma Cell Myeloma |
1.5% |
| Acute Lymphoblastic Leukaemia |
1.1% |
| Pain |
1.0% |
| Sedation |
1.0% |
| Evidence Based Treatment |
0.9% |
| Nausea |
0.9% |
| Antifungal Prophylaxis |
0.8% |
| Febrile Neutropenia |
0.7% |
|
| Sepsis |
18.4% |
| Renal Failure |
8.5% |
| Pancytopenia |
7.8% |
| Febrile Neutropenia |
6.4% |
| Neutropenic Colitis |
6.4% |
| Respiratory Failure |
6.4% |
| Septic Shock |
5.7% |
| Death |
4.3% |
| Neutropenic Sepsis |
4.3% |
| Off Label Use |
4.3% |
| Pyrexia |
4.3% |
| Vomiting |
3.5% |
| Multi-organ Failure |
2.8% |
| Tachycardia |
2.8% |
| Thrombocytopenia |
2.8% |
| White Blood Cell Count Decreased |
2.8% |
| Hypotension |
2.1% |
| Nephrolithiasis |
2.1% |
| Neutropenia |
2.1% |
| Trichosporon Infection |
2.1% |
|
| Concomitant |
| Acute Myeloid Leukaemia |
18.2% |
| Product Used For Unknown Indication |
16.2% |
| Prophylaxis |
10.2% |
| Chemotherapy |
9.5% |
| Prophylaxis Against Graft Versus Host Disease |
6.1% |
| Premedication |
6.0% |
| Bone Marrow Conditioning Regimen |
5.2% |
| Acute Promyelocytic Leukaemia |
3.9% |
| Supplementation Therapy |
3.4% |
| Infection Prophylaxis |
3.2% |
| Transfusion |
3.0% |
| Allergy Prophylaxis |
2.4% |
| Aspergillosis |
2.0% |
| Hypertension |
2.0% |
| Immunosuppressant Drug Therapy |
1.9% |
| T-cell Type Acute Leukaemia |
1.7% |
| Systemic Candida |
1.5% |
| Acute Monocytic Leukaemia |
1.3% |
| Acute Myelomonocytic Leukaemia |
1.1% |
| Myelodysplastic Syndrome |
1.1% |
|
| Drug Ineffective |
19.0% |
| Hy's Law Case |
12.7% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
11.1% |
| Hallucinations, Mixed |
6.3% |
| Vulvovaginal Pruritus |
6.3% |
| Lip Swelling |
4.8% |
| Pancytopenia |
4.8% |
| Retinoic Acid Syndrome |
4.8% |
| White Blood Cell Count Decreased |
4.8% |
| Acute Myeloid Leukaemia |
3.2% |
| Cardiac Tamponade |
3.2% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
3.2% |
| Septic Shock |
3.2% |
| Xerosis |
3.2% |
| Acute Graft Versus Host Disease In Intestine |
1.6% |
| Aspergillosis |
1.6% |
| Benign Intracranial Hypertension |
1.6% |
| Bile Duct Obstruction |
1.6% |
| Bone Marrow Failure |
1.6% |
| Bradycardia |
1.6% |
|
